AstraZeneca Annual Report and Form 20-F Information 2008

Directors' emoluments in 2008

The aggregate remuneration, excluding pension contributions and the value of shares under option and shares subject to performance share plan awards, paid to or accrued for all Directors of the Company for services in all capacities during the year ended 31 December 2008 was £5.9m ($11.1m). The remuneration of individual Directors is set out below in sterling and US dollars. All salaries, fees, bonuses and other benefits for Directors are established in sterling.

DIRECTORS’ REMUNERATION – STERLING

	Salary and fees £000		Bonuses	Taxable benefits £000	Other payments and allowances £000	Total 2008 £000	Total 2007 £000	Total 2006 £000
		Cash £000	Shares1 £000
Louis Schweitzer2	303	–	–	–	–	303	260	260
David Brennan	973	863	432	21	2173	2,506	2,150	2,663
John Patterson	540	348	174	14	54,5	1,081	982	1,007
Simon Lowth	550	469	235	7	434	1,304	172	–
Bo Angelin2	63	–	–	–	–	63	21	–
John Buchanan2	96	–	–	–	–	96	69	69
Jean-Philippe Courtois2,6	58	–	–	–	–	58	–	–
Jane Henney2	76	–	–	–	–	76	57	57
Michele Hooper2	90	–	–	–	–	90	64	49
Rudy Markham7	23	–	–	–	–	23	–	–
Håkan Mogren2	100	–	–	–	–	100	100	100
Nancy Rothwell2	80	–	–	–	–	80	54	30
John Varley2	83	–	–	–	–	83	56	21
Marcus Wallenberg2	53	–	–	–	–	53	40	40
Former Directors	–	–	–	–	–	–	463	1,382
Total	3,088	1,680	841	42	265	5,916	4,488	5,678

¹These figures represent that portion of the 2008 bonuses required to be deferred into shares to be held for a three-year period, as explained in the Bonus Share Deferral Requirements section.

²Fees applicable to all Non-Executive Directors increased during the year, effective from the AGM on 24 April 2008. The revised fees are set out on the Non-Executive Directors’ Fees table.

³Relates to relocation allowances, a car allowance and cash payments in respect of dividends accrued on vesting of a 2005 US performance share plan award.

⁴Relates to remaining cash following selection of benefits within AstraZeneca’s UK flexible benefits programme.

⁵Includes a deduction of £11,000 ($21,000) in respect of member contributions to the AstraZeneca Defined Benefit Programme paid through salary sacrifice (see Pensions section).

⁶Part year only as appointed Director on 18 February 2008.

⁷Part year only as appointed Director on 12 September 2008.

DIRECTORS’ REMUNERATION – US dollars

	Salary and fees $000		Bonuses	Taxable benefits $000	Other payments and allowances $000	Total 2008 $000	Total 2007 $000	Total 2006 $000
		Cash $000	Shares1 $000
Louis Schweitzer2	567	–	–	–	–	567	520	475
David Brennan	1,822	1,616	809	39	4063	4,692	4,300	4,865
John Patterson	1,011	652	326	26	94,5	2,024	1,965	1,839
Simon Lowth	1,030	878	440	13	814	2,442	345	–
Bo Angelin2	118	–	–	–	–	118	42	–
John Buchanan2	180	–	–	–	–	180	138	126
Jean-Philippe Courtois2,6	109	–	–	–	–	109	–	–
Jane Henney2	142	–	–	–	–	142	114	104
Michele Hooper2	169	–	–	–	–	169	128	89
Rudy Markham7	43	–	–	–	–	43	–	–
Håkan Mogren2	187	–	–	–	–	187	200	183
Nancy Rothwell2	150	–	–	–	–	150	108	56
John Varley2	155	–	–	–	–	155	113	39
Marcus Wallenberg2	99	–	–	–	–	99	80	73
Former Directors	–	–	–	–	–	–	929	2,526
Total	5,782	3,146	1,575	78	496	11,077	8,982	10,375

¹These figures represent that portion of the 2008 bonuses required to be deferred into shares to be held for a three-year period, as explained in the Bonus Share Deferral Requirements section.

²Fees applicable to all Non-Executive Directors increased during the year, effective from the AGM on 24 April 2008. The revised fees are set out on the Non-Executive Directors’ Fees table.

³Relates to relocation allowances, a car allowance and cash payments in respect of dividends accrued on vesting of a 2005 US performance share plan award.

⁴Relates to remaining cash following selection of benefits within AstraZeneca’s UK flexible benefits programme.

⁵Includes a deduction of £11,000 ($21,000) in respect of member contributions to the AstraZeneca Defined Benefit Programme paid through salary sacrifice (see Pensions section).

⁶Part year only as appointed Director on 18 February 2008.

⁷Part year only as appointed Director on 12 September 2008.

In the tables above, salaries have been converted between sterling and US dollars at the average exchange rate for the year in question. These rates were:

	GBP/USD
2006	0.547
2007	0.500
2008	0.534

The Executive Directors were also granted options to subscribe for Ordinary Shares and awards of Ordinary Shares under the Company’s long-term incentive arrangements (the AstraZeneca Share Option Plan and the AstraZeneca Performance Share Plan). Details of share options granted to, and exercised by, Directors and the aggregate of gains realised on the exercise of options, and of awards under the long-term incentive plans, in the year are given in each of the Share Options, Gains by Directors on exercise of share options, and AstraZeneca Performance Share Plan tables.

No Director has a family relationship with any other Director.

Back to the top